SteelPeak Wealth 13F: Exits REGN Stake

SteelPeak Wealth cut its entire position in Regeneron Pharmaceuticals, Inc. (REGN) by selling 21,939 shares, according to its latest Form 13F filing with the SEC on October 16, 2026. This marks a complete exit from the stake, which is now down to zero shares.

SteelPeak's divestment reflects a shift in strategy. The fund sold its shares, which had a previous value before the cut but did not disclose a cost basis. After the transaction, Regeneron is now entirely absent from SteelPeak's portfolio.

Other Institutional Activity in Regeneron Pharmaceuticals

Several other institutional investors made recent moves in Regeneron. Blackrock Inc. grew its holdings by 165,537 shares, bringing its total to 9,113,506 shares worth approximately $7.2 billion. Dodge & Cox Inc. increased its position by 412,838 shares, ending with 4,871,137 shares valued at around $3.85 billion. State Street Corporation also added 170,252 shares, raising its stake to 4,834,688 shares worth about $3.82 billion. In contrast, Vanguard Capital Management LLC trimmed its holdings by 25,289 shares, ending with 6,629,759 shares valued at approximately $5.24 billion.

Regeneron Pharmaceuticals, Inc. Stock Holds Steady

Regeneron shares recently traded around $796.21, which is above its 50-day moving average by 0.7% and also above its 200-day average by 8.3%. However, the stock is about 7.3% below its 52-week high of $859.34. The recent price is also below the mean price target of $863.93 set by analysts.

Recent Earnings

Regeneron reported trailing-twelve-month revenues of $15.53 billion, with a net margin of 27.9% and an EPS of $40.44. The company is scheduled to release its next earnings report on October 30, 2026.

Insider Buying and Selling at Regeneron Pharmaceuticals, Inc.

Regeneron's insiders were active with several transactions recently. On August 10, 2026, Director Huda Y Zoghbi sold 800 shares at $800, totaling $640,000. Kathryn Ph.D. Guarini, also a Director, sold 400 shares at $850 on September 2, 2026, for a total of $340,000. Additionally, Officer Marion E Mccourt sold 2,346 shares valued at about $2 million on September 3, 2026. Most recently, Co-Chief Scientific Officer Andrew J. Murphy sold 4,147 shares on October 14, 2026, at an average price of $772.70, totaling approximately $3.2 million.

Analysts Set New Price Targets

On October 6, 2026, JP Morgan maintained its Overweight rating on Regeneron with a price target of $950. Truist Securities followed suit, also maintaining a Buy rating with a target of $780 on October 7, 2026. RBC Capital maintained its Sector Perform rating with a target of $810 on October 8, 2026. UBS upgraded its rating to Buy and set a new target of $978 on October 15, 2026.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company based in Tarrytown, NY. The company focuses on discovering and developing medicines for various diseases, including eye conditions, cancer, and infectious diseases. The filing reflects SteelPeak’s previous holdings and may not represent its current position.

Bottom Line

SteelPeak's complete exit from Regeneron Pharmaceuticals indicates a significant change in strategy. Investors should keep an eye on the upcoming earnings report on October 30, 2026, as well as any future filings that may impact the stock.